Head-to-head evidence
JR-131 vs Pegmolesatide (HS-20039)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
JR-131
Developed by Kissei Pharmaceutical
NCT02912494 · Phase 3 · completed
The study was double-blind and used an active darbepoetin alfa comparator, but the registry does not state whether participants were randomized or report the sample size. Its primary endpoint was change in hemoglobin, a surrogate measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Pegmolesatide (HS-20039)
Marketed by Hansoh Pharmaceutical Group
NCT03902691 · Phase 3 · completed
This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.
Next expected readout: December 2026 · NCT07136792 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JR-131's landscape · Pegmolesatide (HS-20039)'s landscape